On July 6, 2026, a clinical trial update was recorded for the study titled "Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease," registered as NCT07108244. The trial is listed with a phase designation of NA, indicating it does not fall under the standard clinical trial phase classification. Its current status is enrolling by invitation, meaning participants are being recruited through direct invitation rather than open enrollment.
Desmopressin, an approved compound, is associated with this study. No results, efficacy data, or safety findings have been reported as part of this update. The trial record reflects only a change in enrollment status as of the stated date.
This update does not provide information about outcomes, dosing, or clinical benefit. It simply confirms that the study has moved into the enrolling by invitation phase. Readers seeking more information about the trial's design, purpose, or eligibility criteria are encouraged to consult the official registration listing.
For additional background on desmopressin, including its approved uses and general profile, readers can refer to the compound overview.